|Bid||4.56 x 800|
|Ask||5.25 x 800|
|Day's Range||4.74 - 4.87|
|52 Week Range||4.22 - 6.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 18, 2018 - Jul 23, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
DUBLIN, Ireland, June 06, 2018-- Trinity Biotech plc, today announced that Ronan O’ Caoimh, CEO of Trinity Biotech, has increased his shareholding in Trinity Biotech by the acquisition of 430,000 ADRs. ...
The World Health Organization published this month a list of 113 “essential” in vitro diagnostics to guide member states in establishing standards for universal health coverage, inform donation selection ...
DUBLIN, Ireland, May 01, 2018-- Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ...
DUBLIN, April 20, 2018-- Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first ...
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Trinity Biotech Plc Sponsored ADR Class A (NASDAQ: TRIB ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at ...
Categories: Yahoo FinanceGet free summary analysis Trinity Biotech Plc reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Trinity Biotech Plc – Abbott Laboratories, Danaher Corporation and Thermo Fisher Scientific Inc. (ABT-US, DHR-US and TMO-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)
The law firm of Kirby McInerney LLP announced today an investigation on behalf of investors of Trinity Biotech plc concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.